Angiotensin receptor neprilysin inibitor LCZ696 attenuate cardiac remodeling in experimental model of metabolic syndrome

GARCIA RD; GONZALEZ SE; MIATELLO RM; LAMA C; RENNA NF

Mendoza

Congreso; XXII Interamerican Society Congress; 2017

Interamerican Society of Hypertension

Hypertension is a major causes of death and morbidity in the Western world, and their prevalence is projected to increase. Increasing recognition that sustained overdrive of neurohormonal systems such as the renin?angiotensin?aldosterone system (RAAS) is involved in hypertension pathophysiology has led to the introduction of drugs inhibiting key components of the RAAS into clinical practice. The aim of this study was demonstrate the participation of LCZ969 (L) in cardiovascular remodeling. Methods: Male WKY and SHR were separated into five groups: Control, FFR: WKY rats receiving a 10% (w/v) fructose solution during all 12 weeks, SHR, FFHR: SHR receiving a 10% (w/v) fructose solution during all 12 weeks and FFHR+S: (68 mg/kg per day for 6 weeks) (n=8 each group). Metabolic variables and systolic blood pressure were measured. Cardiac remodelling was also evaluated. Results: L reverted a increase in systolic blood pressure and do not modify metabolic laboratory variables. Thus chronic administration of L was able to revert cardiovascular hypertrophy. Conclusion: All these data suggest the involvement of RAAS and NEP system on the expression of different inflammatory and growth factors proteins in myocardial area, allowing the creation, perpetuity, amplification and destabilization of cardiovascular injury.